Moertel Criticizes Janssen Over Levamisole Price, Delivers Final Report On Intergroup Adjuvant Trial
In Brief: Seffrin’s ACS Appointment Is Official; Liotta Selected As NIH; Strategic Plan Meetings
Other ASCO Plenary Papers: Long Awaited Chemotherapy Results
Congress Okays NIH Reauthorization, Allows NCI $472 Mil. More
Gallo Inquiry Complete; NCAB’s AIDS Committee Plans Q&A Session
NCAB Decides To End IGs, Review total Research Support, And Consider P01 Limitation
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”









